rs80358824
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000059.4(BRCA2):c.5909C>A(p.Ser1970Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000479 in 1,461,696 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. S1970S) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000059.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BRCA2 | NM_000059.4 | c.5909C>A | p.Ser1970Ter | stop_gained | 11/27 | ENST00000380152.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.5909C>A | p.Ser1970Ter | stop_gained | 11/27 | 5 | NM_000059.4 | A2 |
Frequencies
GnomAD3 genomes ? Cov.: 33
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461696Hom.: 0 Cov.: 46 AF XY: 0.00000688 AC XY: 5AN XY: 727152
GnomAD4 genome ? Cov.: 33
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:9
Pathogenic, no assertion criteria provided | clinical testing | Institute of Human Genetics, Medical University Innsbruck | Feb 11, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge | Oct 02, 2015 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Sharing Clinical Reports Project (SCRP) | Jan 10, 2012 | - - |
Pathogenic, reviewed by expert panel | curation | Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) | Apr 22, 2016 | Variant allele predicted to encode a truncated non-functional protein. - |
Pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Nov 28, 2023 | This variant changes 1 nucleotide in exon 11 of the BRCA2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with breast and/or ovarian cancer (PMID: 8988179,10359546, 11844822, 14672397, 19329713, 21120943, 24728189, 25682074, 27153395, 27469594), and prostate cancer (PMID: 24556621). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA2) | May 29, 2002 | - - |
Pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 29, 2020 | The p.Ser1970Ter variant in BRCA2 has been reported in at least 11 individuals with breast or ovarian cancer, including at least 6 individuals with a family history of that cancer (PMID: 14672397, 11844822, 10359546, 27469594, 25682074, 23754601, 27153395, 8988179, 24728189), at least 2 male individuals with prostate cancer (PMID: 20736950, 24556621), and 2 individuals with a family history of cancer (PMID: 19329713), and was absent from large population studies. This variant has also been reported pathogenic in ClinVar (Variation ID: 38007). This nonsense variant leads to a premature termination codon at position 1970, which is predicted to lead to a truncated or absent protein. Heterozygous loss of function of the BRCA2 gene is an established disease mechanism in hereditary susceptibility to breast and ovarian cancer. In summary, this variant meets criteria to be classified as pathogenic for hereditary susceptibility to breast and ovarian cancer in an autosomal dominant manner based on the predicted impact of the variant, multiple occurrences of the variant in affected individuals, and absence in the general population. ACMG/AMP Criteria applied: PVS1, PS4, PM2 (Richards 2015). - |
Pathogenic, criteria provided, single submitter | clinical testing | Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine | Feb 21, 2019 | This variant in the BRCA2 gene is predicted to result in an early stop codon, and loss of function variants are a known pathogenic mechanism of this gene. This variant has been observed in at least three HBOC families (PMID 8988179, 11844822 and 24556621). Additionally, it has been seen in multiple ovarian cancer cases (PMID 24728189), early onset breast cancer (PMID 27469594), and triple negative breast cancer (PMID 25682074). This variant has not been observed in the population database gnomAD, and was absent from specific study controls (PMID 24728189). Therefore, the c.5909C>A (p.Ser1970*) variant in the BRCA2 gene is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Feb 27, 2018 | - - |
Hereditary breast ovarian cancer syndrome Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 27, 2024 | This sequence change creates a premature translational stop signal (p.Ser1970*) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with hereditary breast and ovarian cancer and prostate cancer (PMID: 8988179, 20736950, 21120943, 24556621, 24728189, 25682074, 27225819, 27469594). This variant is also known as 6137C>A. ClinVar contains an entry for this variant (Variation ID: 38007). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 11, 2023 | Variant summary: BRCA2 c.5909C>A (p.Ser1970X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 250902 control chromosomes. c.5909C>A has been reported in the literature in multiple individuals affected with Hereditary Breast And Ovarian Cancer Syndrome. These data indicate that the variant is very likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 10359546, 8988179, 20736950, 11844822, 14672397, 24556621, 23754601). 13 submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | research | Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto | Jan 31, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Department of Pathology and Molecular Medicine, Queen's University | Apr 20, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 14, 2019 | The p.Ser1970X (c.5682C>A) variant in BRCA2 has been reported in at least 12 individuals with BRCA2-related cancers (Gayther 1997, Edwards 2010, Leongamornlert 2014, Labidi-Galy 2018, BIC database) and was absent from large population studies. This nonsense variant is predicted to lead to a premature termination codon at position 1970, which is predicted to lead to a truncated or absent protein. Loss of function of the BRCA2 gene is an established disease mechanism in autosomal dominant hereditary breast and ovarian cancer syndrome (HBOC). Additionally, this variant was classified as Pathogenic on Apr 22, 2016 by the ClinGen-approved ENIGMA expert panel (Variation ID: 38007). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HBOC. ACMG/AMP Criteria applied: PVS1, PM2, PS4_Moderate. - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics and Genomics, Karolinska University Hospital | Jan 13, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Apr 23, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 31, 2022 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (Gayther 1997, Shih 2002, Al-Mulla 2009, Leongamornlert 2014, Song 2014, Maxwell 2016, Donenberg 2019); Not observed at significant frequency in large population cohorts (gnomAD); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Also known as 6137C>A; This variant is associated with the following publications: (PMID: 17688236, 11938448, 20609467, 8988179, 24556621, 21120943, 20736950, 25682074, 19329713, 25525159, 27225819, 10359546, 24728189, 15131399, 11844822, 27153395, 30515680, 33646313, 29084914, 31090900, 29446198, 30787465, 33087929) - |
Hereditary cancer-predisposing syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 04, 2022 | The p.S1970* pathogenic mutation (also known as c.5909C>A), located in coding exon 10 of the BRCA2 gene, results from a C to A substitution at nucleotide position 5909. This changes the amino acid from a serine to a stop codon within coding exon 10. This mutation has been observed in multiple individuals and families with breast and/or ovarian cancers (Leongamornlert D et al. Br. J. Cancer. 2014 Mar;110:1663-72; Wong-Brown MW et al. Breast Cancer Res. Treat. 2015 Feb;150:71-80; Maxwell KN et al. Am. J. Hum. Genet. 2016 May;98:801-17; Donenberg T et al. Breast Cancer Res. Treat. 2016 Aug;159:131-8; Song H et al. Hum. Mol. Genet. 2014 Sep;23:4703-9; Dominguez-Valentin M et al. Hered Cancer Clin Pract, 2018 Jan;16:4; Nones K et al. Ann Oncol, 2019 07;30:1071-1079; Abe T et al. J Clin Oncol, 2019 05;37:1070-1080; Labidi-Galy SI et al. Clin Cancer Res, 2018 01;24:326-333; Caux-Moncoutier V et al. Hum Mutat, 2011 Mar;32:325-34; Al-Mulla F et al. J Clin Pathol, 2009 Apr;62:350-6; Nedelcu R et al. Eur J Hum Genet, 2002 Feb;10:150-2; Peto J et al. J Natl Cancer Inst, 1999 Jun;91:943-9). Of note, this alteration is also designed as 6137C>A in published literature. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | May 31, 2022 | This variant changes 1 nucleotide in exon 11 of the BRCA2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with breast and/or ovarian cancer (PMID: 8988179,10359546, 11844822, 14672397, 19329713, 21120943, 24728189, 25682074, 27153395, 27469594), and prostate cancer (PMID: 24556621). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
Breast and/or ovarian cancer Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Foulkes Cancer Genetics LDI, Lady Davis Institute for Medical Research | - | - - |
Malignant tumor of breast Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The BRCA2 p.Ser1970X variant was identified in 7 of 3852 proband chromosomes (frequency: 0.0018) from individuals or families with breast, ovarian and prostate cancer (Al-Mulla_2008_19329713 , Gayther_1997_8988179, Leongamornlert_2014_24556621, Lubinski_2004_15131399 , Shih_2002_11844822 , Wong-Brown_2015_25682074). The variant was also identified in dbSNP (ID: rs80358824) as “With Pathogenic allele”, ClinVar (as pathogenic, reviewed by expert panel), Clinvitae (5x as pathogenic), GeneInsight-COGR (as pathogenic), LOVD 3.0 (3x as pathogenic), UMD-LSDB (56x as causal), and ARUP Laboratories (as "definitely pathogenic"). The variant was not identified in Cosmic, MutDB, BIC Database, Zhejiang Colon Cancer Database. The variant was not identified in the following control databases: the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). In addition, a UK survival study of 2 groups of men with prostate cancer diagnosed at similar ages, showed that men harbouring deleterious germline BRCA2 mutations had a poorer survival outcome than those who did not carry BRCA2 mutations, with 4.8 vs 8.5 years survival rate (Edwards_2010_20736950). The p.Ser1970X variant leads to a premature stop codon at position 1970 which is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants of the BRCA2 gene are an established mechanism of disease in hereditary breast and ovarian cancer and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. - |
Familial cancer of breast Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jun 20, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at